Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)

Written2007-12Nadia Gabellini
University of Padua, Department of Biological Chemistry, Viale G. Colombo, 3; 35131, Padua, Italy

(Note : for Links provided by Atlas : click)

Identity

Other namesGP145-TrkB
TRKB
Trk-B
HGNC (Hugo) NTRK2
LocusID (NCBI) 4915
Atlas_Id 41589
Location 9q21.33  [Link to chromosome band 9q21]
Location_base_pair Starts at 87284595 and ends at 87430623 bp from pter ( according to hg19-Feb_2009)  [Mapping NTRK2.png]
Local_order NTRK2 is located between solute carrier family 28, sodium-coupled nucleoside transporter member 3 (SLC28A3) and ATP/GTP binding protein 1 (AGTPBP1).
Fusion genes
(updated 2016)
AFAP1 (4p16.1) / NTRK2 (9q21.33)AGBL4 (1p33) / NTRK2 (9q21.33)NACC2 (9q34.3) / NTRK2 (9q21.33)
NAV1 (1q32.1) / NTRK2 (9q21.33)NTRK2 (9q21.33) / LAP3 (4p15.32)NTRK2 (9q21.33) / NTRK2 (9q21.33)
NTRK2 (9q21.33) / RASEF (9q21.32)PAN3 (13q12.2) / NTRK2 (9q21.33)QKI (6q26) / NTRK2 (9q21.33)
SQSTM1 (5q35.3) / NTRK2 (9q21.33)TRIM24 (7q33) / NTRK2 (9q21.33)VCL (10q22.2) / NTRK2 (9q21.33)

DNA/RNA

 
  Figure 1: The horizontal bar represents NTRK2 gene (355,039 bp). Vertical bars depict the exons 1-24 (red: translated regions, blue: 5' and 3' UTR regions).
Table 1: NTRK2 exons and size (bp).
Description NTRK2 gene is comprised between 86,473,286-86,828,325 bp of chromosome 9, with plus strand orientation. The start codon is located on exon 5. Alternative stop codons are placed on terminal exons 16, 19 and 24.
Transcription According to AceView (NCBI), six alternative promoters may control transcription of the complex NTRK2 locus. There are at least 18 mRNA variants supported by cDNA clones, potentially encoding 12 complete proteins. Variants may include 8 different terminal exons with alternative polyadenylation sites. Truncation at the 5' end or 3' end, alternative splicing, intron retention, occurrence of 5 cassette exons, and different exon boundaries introduce additional differences.
Five confirmed mRNA variants (a, b, c, d, e) are reported (NCBI accessions: NM_006180.3; NM_001007097.1; NM_001018064.1; NM_001018065.1; NM_001018066.1). The mRNA variant (a) encodes the full-length protein; variant (c) is slightly shorter excluding the small internal exon 17. Of particular importance are the truncated isoforms lacking the catalytic tyrosine kinase domain generated by the inclusion of alternate terminal exon 16 (b) or exon 19 (d) and (e).
Pseudogene None

Protein

Note Three TrkB isoforms are reported by UniProt/Swiss-Prot:
1. The long isoform TrkB, including the tyrosine kinase domain (ID Q16620-1; variant c).
2. The truncated isoform TrkB-T1 lacking the tyrosine kinase domain (ID Q16620-2; variant b).
3. The truncated isoform TrkB-T-Shc lacking the tyrosine kinase domain but retaining the Shc site (ID Q16620-3; variant e).
 
  The predicted domains of TrkB (variant c): Signal Peptide (SP, AA 1-31); Leucine Rich Repeat N-Terminal domain (LRRNT, AA 31-65); Leucine-rich Repeats (LRR, AA 72-93, 96-117, 116-138); Leucine Rich Repeat C-Terminal domain (LRRCT, AA 148-195); Immunoglobulin C-2 Type 1 domain (IGC2-1, AA 197-282); Immunoglobulin C-2-type 2 domain (IGC2-2, AA 295-365); Transmembrane (TM, AA 431-454); the Protein Kinase domain (TyrKc, AA 538-807). In addition the site of interaction with SHC1 (Shc, AA 516) and with Phospho-Lipase C-gamma-1 (AA PLC-gamma, 817) are indicated.
Description The unprocessed precursor of the full-length TrkB (a) consists of 838 AA. Variant (c) excludes 16 AA of unknown function, located downstream of the transmembrane segment.
The N-terminal portion (AA 32-430) is potentially extracellular and includes several N-glycosylation sites (AA 67, 121, 254). It follows a single transmembrane segment (AA 432-454). The C-terminal portion is cytosolic (AA 455-822) and comprises the Protein Kinase domain. This region includes the ATP binding site (AA 544-552) and several sites of autophosphorylation such as Tyr-516/702/706/707/817 (AA position refers to variant c).
The truncated Trkb-T1 (b) is composed of 477 AA. TrkB-T-Shc variants d and e consist of 553 AA and 537 AA, respectively. Truncated isoforms TrkB-T1 and TrkB-T-Shc include C-terminal sequence variations of 10 and 9 AA, respectively.
Expression NTRK2 gene is preferentially expressed in brain, spinal cord, cranial and spinal ganglia. Expression is most prominent in the following brain regions: amygdale, caudate nucleus, cerebellum, choroid plexus, corpus callosum, cortex, hippocampus, hypothalamus and thalamus. In addition, a variety of cranial structures such as eyes, ophthalmic nerves, various facial districts and vestibular system indicate significant expression. Lower expression is described in several other tissues such as heart, kidney, lung, ovaries, pancreas, pituitary gland, prostate, salivary glands, skeletal muscle, spleen, thymus and thyroid.
Isoforms TrkB and TrkB-T1 are expressed in brain as well as in several peripheral areas, whereas TrkB-T-Shc is primarily expressed in brain.
AceView (NCBI) analysis of cDNA clones supports the expression pattern suggested by the evaluation of mRNA described above. In addition suggests elevated expression in several tumor tissues.
Localisation Neuronal activity promotes TrkB translocation from intracellular vesicles to the plasma membrane where it becomes available for neurotrophins. The N-terminal segment is extracellular and is involved in neurotrophin binding and cell adhesion. A single transmembrane segment is located in the central portion of the polypeptide. The C-terminal segment is intracellular and comprises the protein kinase domain.
Function TrkB specifically binds brain-derived neurotrophic factor (BDNF) and neurotrophin 4/5. It can also bind neurotrophin-3 with low affinity but it excludes nerve growth factor (NGF). Neurotrophin binding triggers receptor dimerization and consequent trans-phosphorylation of tyrosine residues of the TyrKc domain. Phosphorylated receptor undergoes conformational changes, which promote the recruitment of intracellular substrates such SHC1, PI-3 kinase, and PLC-gamma-1. The signaling cascades consequently activated support neuronal survival during development and following injuries, promote neuronal differentiation and maintenance, control short-term and long-term synaptic activity. TrkB can also form heterodimers with the pan-neurotrophin receptor p75NTR or with truncated TrkB. This influences the establishment of specific connections with signaling pathways.
Homology TrkB belongs to the large family of protein kinase comprising a conserved kinase domain. It is included in the subfamily of tyrosine protein kinase. For the presence of a highly conserved intracellular TyrKc domain it is most related to growth factor receptors, and particularly to the neurotrophic factor receptors TrkA and TrkC. The homology with tyrosine kinase receptors is extended to the IGC-2 and LRRs domains, however, these are also present in cell-adhesion molecules.

Mutations

Germinal Heterozygous missense mutations leading to substitution of highly conserved residues have been linked to Obesity, Hyperphagia and Developmental Delay.
Recurrent SNPs of the NTRK2 locus are associated with Eating Disorders (Anorexia and Bulimia nervosa).
Somatic Tumor-specific mutations in the kinase domain have been identified in Colorectal Cancer cells.

Implicated in

Note
Entity Various diseases
Disease Obesity, Hyperphagia and Developmental Delay. Neuroblastomas, Pancreatic Ductal Adenocarcinomas, Wilms's tumors, Colorectal Cancer.
Oncogenesis Overexpression of full-length TrkB is generally associated with malignant transformation. Excessive TrkB signaling through MAPK, PI3K and mTOR pathways support tumor development and metastasis. In highly malignant tumors the overexpression of TrkB enhances angiogenesis and invasive potential by upregulating VEGF and matrix proteases. Furthermore TrkB overcomes apoptosis caused by loss of cell-matrix interactions (anoikis), which is a natural barrier to metastasis.
In contrast with the oncogenic activity of TrkB, the truncated isoforms TrkB-T1 and TrkB-T-Shc, lacking the tyrosine kinase domain, behave as dominant-negative inhibitors and counteract tumor growth.
  

To be noted

NTRK2 gene is comprised in the region, del(9q), commonly deleted in acute myeloid leukemia, this disease is believed to arise by heterozygous loss of tumor suppressor genes.
Numerous structural abnormalities of the region 9q22 are associated with cancer cases reported by The Cancer Genome Anatomy Project (CGAP).

Bibliography

Human neuroblastomas with unfavorable biologies express high levels of brain-derived neurotrophic factor mRNA and a variety of its variants.
Aoyama M, Asai K, Shishikura T, Kawamoto T, Miyachi T, Yokoi T, Togari H, Wada Y, Kato T, Nakagawara A
Cancer letters. 2001 ; 164 (1) : 51-60.
PMID 11166915
 
Mutational analysis of the tyrosine kinome in colorectal cancers.
Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, Willson JK, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE
Science (New York, N.Y.). 2003 ; 300 (5621) : page 949.
PMID 12738854
 
Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB.
Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS
Nature. 2004 ; 430 (7003) : 1034-1039.
PMID 15329723
 
Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis.
Geiger TR, Peeper DS
Cancer research. 2007 ; 67 (13) : 6221-6229.
PMID 17616679
 
Neurotrophic receptor TrkB: Is it a predictor of poor prognosis for carcinoma patients?
Han L, Zhang Z, Qin W, Sun W
Medical hypotheses. 2007 ; 68 (2) : 407-409.
PMID 17008023
 
The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness.
Hecht M, Schulte JH, Eggert A, Wilting J, Schweigerer L
Carcinogenesis. 2005 ; 26 (12) : 2105-2115.
PMID 16051641
 
trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development.
Klein R, Parada LF, Coulier F, Barbacid M
The EMBO journal. 1989 ; 8 (12) : 3701-3709.
PMID 2555172
 
Identification of TrkB autophosphorylation sites and evidence that phospholipase C-gamma 1 is a substrate of the TrkB receptor.
Middlemas DS, Meisenhelder J, Hunter T
The Journal of biological chemistry. 1994 ; 269 (7) : 5458-5466.
PMID 8106527
 
Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2).
Nakagawara A, Liu XG, Ikegaki N, White PS, Yamashiro DJ, Nycum LM, Biegel JA, Brodeur GM
Genomics. 1995 ; 25 (2) : 538-546.
PMID 7789988
 
Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells.
Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW, Thiele CJ
Cancer research. 2006 ; 66 (8) : 4249-4255.
PMID 16618748
 
p75NTR--live or let die.
Nykjaer A, Willnow TE, Petersen CM
Current opinion in neurobiology. 2005 ; 15 (1) : 49-57.
PMID 15721744
 
Contribution of NTRK2 to the genetic susceptibility to anorexia nervosa, harm avoidance and minimum body mass index.
Ribases M, Gratacos M, Badia A, Jimenez L, Solano R, Vallejo J, Fernandez-Aranda F, Estivill X
Molecular psychiatry. 2005 ; 10 (9) : 851-860.
PMID 15838534
 
A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trkB tyrosine kinase receptors.
Schneider R, Schweiger M
Oncogene. 1991 ; 6 (10) : 1807-1811.
PMID 1656363
 
Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells.
Sclabas GM, Fujioka S, Schmidt C, Li Z, Frederick WA, Yang W, Yokoi K, Evans DB, Abbruzzese JL, Hess KR, Zhang W, Fidler IJ, Chiao PJ
Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 ; 11 (2 Pt 1) : 440-449.
PMID 15701826
 
The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor.
Soppet D, Escandon E, Maragos J, Middlemas DS, Reid SW, Blair J, Burton LE, Stanton BR, Kaplan DR, Hunter T
Cell. 1991 ; 65 (5) : 895-903.
PMID 1645620
 
trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor.
Squinto SP, Stitt TN, Aldrich TH, Davis S, Bianco SM, Radziejewski C, Glass DJ, Masiakowski P, Furth ME, Valenzuela DM
Cell. 1991 ; 65 (5) : 885-893.
PMID 1710174
 
Analysis of the human TrkB gene genomic organization reveals novel TrkB isoforms, unusual gene length, and splicing mechanism.
Stoilov P, Castren E, Stamm S
Biochemical and biophysical research communications. 2002 ; 290 (3) : 1054-1065.
PMID 11798182
 
Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia.
Sweetser DA, Peniket AJ, Haaland C, Blomberg AA, Zhang Y, Zaidi ST, Dayyani F, Zhao Z, Heerema NA, Boultwood J, Dewald GW, Paietta E, Slovak ML, Willman CL, Wainscoat JS, Bernstein ID, Daly SB
Genes, chromosomes & cancer. 2005 ; 44 (3) : 279-291.
PMID 16015647
 
Signal transduction by receptors with tyrosine kinase activity.
Ullrich A, Schlessinger J
Cell. 1990 ; 61 (2) : 203-212.
PMID 2158859
 
A de novo mutation affecting human TrkB associated with severe obesity and developmental delay.
Yeo GS, Connie Hung CC, Rochford J, Keogh J, Gray J, Sivaramakrishnan S, O'Rahilly S, Farooqi IS
Nature neuroscience. 2004 ; 7 (11) : 1187-1189.
PMID 15494731
 

Citation

This paper should be referenced as such :
Gabellini, N
NTRK2 (neurotrophic tyrosine kinase, receptor, type 2)
Atlas Genet Cytogenet Oncol Haematol. 2008;12(4):314-317.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/NTRK2ID41589ch9q21.html


External links

Nomenclature
HGNC (Hugo)NTRK2   8032
Cards
AtlasNTRK2ID41589ch9q21
Entrez_Gene (NCBI)NTRK2  4915  neurotrophic receptor tyrosine kinase 2
AliasesGP145-TrkB; TRKB; trk-B
GeneCards (Weizmann)NTRK2
Ensembl hg19 (Hinxton)ENSG00000148053 [Gene_View]  chr9:87284595-87430623 [Contig_View]  NTRK2 [Vega]
Ensembl hg38 (Hinxton)ENSG00000148053 [Gene_View]  chr9:87284595-87430623 [Contig_View]  NTRK2 [Vega]
ICGC DataPortalENSG00000148053
TCGA cBioPortalNTRK2
AceView (NCBI)NTRK2
Genatlas (Paris)NTRK2
WikiGenes4915
SOURCE (Princeton)NTRK2
Genomic and cartography
GoldenPath hg19 (UCSC)NTRK2  -     chr9:87284595-87430623 +  9q22.1   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)NTRK2  -     9q22.1   [Description]    (hg38-Dec_2013)
EnsemblNTRK2 - 9q22.1 [CytoView hg19]  NTRK2 - 9q22.1 [CytoView hg38]
Mapping of homologs : NCBINTRK2 [Mapview hg19]  NTRK2 [Mapview hg38]
OMIM600456   613886   
Gene and transcription
Genbank (Entrez)AB209118 AF086101 AF400441 AF410898 AF410899
RefSeq transcript (Entrez)NM_001007097 NM_001018064 NM_001018065 NM_001018066 NM_001291937 NM_006180
RefSeq genomic (Entrez)NC_000009 NC_018920 NG_012201 NT_008470 NW_004929366
Consensus coding sequences : CCDS (NCBI)NTRK2
Cluster EST : UnigeneHs.712776 [ NCBI ]
CGAP (NCI)Hs.712776
Alternative Splicing GalleryENSG00000148053
Gene ExpressionNTRK2 [ NCBI-GEO ]   NTRK2 [ EBI - ARRAY_EXPRESS ]   NTRK2 [ SEEK ]   NTRK2 [ MEM ]
Gene Expression Viewer (FireBrowse)NTRK2 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)4915
GTEX Portal (Tissue expression)NTRK2
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ16620 (Uniprot)
NextProtQ16620  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ16620
Splice isoforms : SwissVarQ16620 (Swissvar)
Catalytic activity : Enzyme2.7.10.1 [ Enzyme-Expasy ]   2.7.10.12.7.10.1 [ IntEnz-EBI ]   2.7.10.1 [ BRENDA ]   2.7.10.1 [ KEGG ]   
PhosPhoSitePlusQ16620
Domaine pattern : Prosite (Expaxy)IG_LIKE (PS50835)    PROTEIN_KINASE_ATP (PS00107)    PROTEIN_KINASE_DOM (PS50011)    PROTEIN_KINASE_TYR (PS00109)    RECEPTOR_TYR_KIN_II (PS00239)   
Domains : Interpro (EBI)Cys-rich_flank_reg_C    Ig-like_dom    Ig-like_fold    Ig_I-set    Ig_sub2    Kinase-like_dom    L_dom-like    Leu-rich_rpt    LRRNT    NTRK_C2    Prot_kinase_dom    Protein_kinase_ATP_BS    Ser-Thr/Tyr_kinase_cat_dom    Tyr_kin_neurotrophic_rcpt_2    Tyr_kinase_AS    Tyr_kinase_cat_dom    Tyr_kinase_NGF_rcpt    Tyr_kinase_rcpt_2_CS   
Domain families : Pfam (Sanger)I-set (PF07679)    LRR_8 (PF13855)    LRRNT (PF01462)    Pkinase_Tyr (PF07714)    TPKR_C2 (PF16920)   
Domain families : Pfam (NCBI)pfam07679    pfam13855    pfam01462    pfam07714    pfam16920   
Domain families : Smart (EMBL)IGc2 (SM00408)  LRRCT (SM00082)  LRRNT (SM00013)  TyrKc (SM00219)  
DMDM Disease mutations4915
Blocks (Seattle)NTRK2
PDB (SRS)1HCF    1WWB    2MFQ    4ASZ    4AT3    4AT4    4AT5   
PDB (PDBSum)1HCF    1WWB    2MFQ    4ASZ    4AT3    4AT4    4AT5   
PDB (IMB)1HCF    1WWB    2MFQ    4ASZ    4AT3    4AT4    4AT5   
PDB (RSDB)1HCF    1WWB    2MFQ    4ASZ    4AT3    4AT4    4AT5   
Structural Biology KnowledgeBase1HCF    1WWB    2MFQ    4ASZ    4AT3    4AT4    4AT5   
SCOP (Structural Classification of Proteins)1HCF    1WWB    2MFQ    4ASZ    4AT3    4AT4    4AT5   
CATH (Classification of proteins structures)1HCF    1WWB    2MFQ    4ASZ    4AT3    4AT4    4AT5   
SuperfamilyQ16620
Human Protein AtlasENSG00000148053
Peptide AtlasQ16620
HPRD02712
IPIIPI00003366   IPI00478527   IPI00179433   IPI01010072   IPI00604575   IPI00163641   
Protein Interaction databases
DIP (DOE-UCLA)Q16620
IntAct (EBI)Q16620
FunCoupENSG00000148053
BioGRIDNTRK2
STRING (EMBL)NTRK2
ZODIACNTRK2
Ontologies - Pathways
QuickGOQ16620
Ontology : AmiGOvasculogenesis  neuron migration  positive regulation of protein phosphorylation  ATP binding  rough endoplasmic reticulum  cytosol  integral component of plasma membrane  inflammatory response  neuromuscular junction development  aging  learning  long-term memory  circadian rhythm  feeding behavior  positive regulation of cell proliferation  response to light stimulus  cell surface  endosome membrane  positive regulation of gene expression  positive regulation of neuron projection development  response to auditory stimulus  glutamate secretion  positive regulation of phosphatidylinositol 3-kinase signaling  peptidyl-tyrosine phosphorylation  central nervous system neuron development  cerebral cortex development  neuron differentiation  growth cone  receptor tyrosine kinase binding  brain-derived neurotrophic factor receptor signaling pathway  brain-derived neurotrophic factor receptor signaling pathway  positive regulation of peptidyl-serine phosphorylation  calcium-mediated signaling using intracellular calcium source  neurotrophin signaling pathway  mechanoreceptor differentiation  protein homodimerization activity  regulation of GTPase activity  neurotrophin binding  neurotrophin binding  terminal bouton  dendritic spine  perikaryon  receptor complex  positive regulation of MAPK cascade  negative regulation of neuron apoptotic process  postsynaptic membrane  retinal rod cell development  protein autophosphorylation  regulation of neurotransmitter secretion  brain-derived neurotrophic factor binding  oligodendrocyte differentiation  presynaptic active zone  peripheral nervous system neuron development  positive regulation of axonogenesis  regulation of dendrite development  regulation of protein kinase B signaling  positive regulation of synapse assembly  positive regulation of synaptic transmission, glutamatergic  retina development in camera-type eye  brain-derived neurotrophic factor-activated receptor activity  long-term synaptic potentiation  cellular response to amino acid stimulus  cellular response to tumor necrosis factor  neuronal postsynaptic density  cellular response to brain-derived neurotrophic factor stimulus  negative regulation of anoikis  
Ontology : EGO-EBIvasculogenesis  neuron migration  positive regulation of protein phosphorylation  ATP binding  rough endoplasmic reticulum  cytosol  integral component of plasma membrane  inflammatory response  neuromuscular junction development  aging  learning  long-term memory  circadian rhythm  feeding behavior  positive regulation of cell proliferation  response to light stimulus  cell surface  endosome membrane  positive regulation of gene expression  positive regulation of neuron projection development  response to auditory stimulus  glutamate secretion  positive regulation of phosphatidylinositol 3-kinase signaling  peptidyl-tyrosine phosphorylation  central nervous system neuron development  cerebral cortex development  neuron differentiation  growth cone  receptor tyrosine kinase binding  brain-derived neurotrophic factor receptor signaling pathway  brain-derived neurotrophic factor receptor signaling pathway  positive regulation of peptidyl-serine phosphorylation  calcium-mediated signaling using intracellular calcium source  neurotrophin signaling pathway  mechanoreceptor differentiation  protein homodimerization activity  regulation of GTPase activity  neurotrophin binding  neurotrophin binding  terminal bouton  dendritic spine  perikaryon  receptor complex  positive regulation of MAPK cascade  negative regulation of neuron apoptotic process  postsynaptic membrane  retinal rod cell development  protein autophosphorylation  regulation of neurotransmitter secretion  brain-derived neurotrophic factor binding  oligodendrocyte differentiation  presynaptic active zone  peripheral nervous system neuron development  positive regulation of axonogenesis  regulation of dendrite development  regulation of protein kinase B signaling  positive regulation of synapse assembly  positive regulation of synaptic transmission, glutamatergic  retina development in camera-type eye  brain-derived neurotrophic factor-activated receptor activity  long-term synaptic potentiation  cellular response to amino acid stimulus  cellular response to tumor necrosis factor  neuronal postsynaptic density  cellular response to brain-derived neurotrophic factor stimulus  negative regulation of anoikis  
Pathways : KEGGMAPK signaling pathway    Neurotrophin signaling pathway    Alcoholism   
REACTOMEQ16620 [protein]
REACTOME PathwaysR-HSA-187024 NGF-independant TRKA activation [pathway]
NDEx Network
Atlas of Cancer Signalling NetworkNTRK2
Wikipedia pathwaysNTRK2
Orthology - Evolution
OrthoDB4915
GeneTree (enSembl)ENSG00000148053
Phylogenetic Trees/Animal Genes : TreeFamNTRK2
Homologs : HomoloGeneNTRK2
Homology/Alignments : Family Browser (UCSC)NTRK2
Gene fusions - Rearrangements
Fusion : MitelmanAFAP1/NTRK2 [4p16.1/9q21.33]  [t(4;9)(p16;q21)]  
Fusion : MitelmanAGBL4/NTRK2 [1p33/9q21.33]  [t(1;9)(p33;q21)]  
Fusion : MitelmanNACC2/NTRK2 [9q34.3/9q21.33]  [t(9;9)(q21;q34)]  
Fusion : MitelmanNAV1/NTRK2 [1q32.1/9q21.33]  [t(1;9)(q32;q21)]  
Fusion : MitelmanNTRK2/LAP3 [9q21.33/4p15.32]  [t(4;9)(p15;q21)]  
Fusion : MitelmanNTRK2/RASEF [9q21.33/9q21.32]  [t(9;9)(q21;q21)]  
Fusion : MitelmanPAN3/NTRK2 [13q12.2/9q21.33]  [t(9;13)(q21;q12)]  
Fusion : MitelmanQKI/NTRK2 [6q26/9q21.33]  [t(6;9)(q26;q21)]  
Fusion : MitelmanTRIM24/NTRK2 [7q33/9q21.33]  [t(7;9)(q34;q21)]  
Fusion : MitelmanVCL/NTRK2 [10q22.2/9q21.33]  [t(9;10)(q21;q22)]  
Fusion : COSMICQKI [6q26]  -  NTRK2 [9q21.33]  [fusion_1446]  [fusion_1447]  
Fusion: TCGAAFAP1 4p16.1 NTRK2 9q21.33 LGG
Fusion: TCGANTRK2 9q21.33 LAP3 4p15.32 LGG
Fusion: TCGANTRK2 9q21.33 RASEF 9q21.32 BRCA
Fusion: TCGAPAN3 13q12.2 NTRK2 9q21.33 HNSC
Fusion: TCGATRIM24 7q33 NTRK2 9q21.33 LUAD
Polymorphisms : SNP, variants
NCBI Variation ViewerNTRK2 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)NTRK2
dbVarNTRK2
ClinVarNTRK2
1000_GenomesNTRK2 
Exome Variant ServerNTRK2
ExAC (Exome Aggregation Consortium)NTRK2 (select the gene name)
Genetic variants : HAPMAP4915
Genomic Variants (DGV)NTRK2 [DGVbeta]
Mutations
ICGC Data PortalNTRK2 
TCGA Data PortalNTRK2 
Broad Tumor PortalNTRK2
OASIS PortalNTRK2 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICNTRK2 
intOGen PortalNTRK2
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch NTRK2
DgiDB (Drug Gene Interaction Database)NTRK2
DoCM (Curated mutations)NTRK2 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)NTRK2 (select a term)
intoGenNTRK2
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] 
Diseases
DECIPHER (Syndromes)9:87284595-87430623  ENSG00000148053
CONAN: Copy Number AnalysisNTRK2 
Mutations and Diseases : HGMDNTRK2
OMIM600456    613886   
MedgenNTRK2
Genetic Testing Registry NTRK2
NextProtQ16620 [Medical]
TSGene4915
GENETestsNTRK2
Huge Navigator NTRK2 [HugePedia]
snp3D : Map Gene to Disease4915
BioCentury BCIQNTRK2
ClinGenNTRK2
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD4915
Chemical/Pharm GKB GenePA31818
Clinical trialNTRK2
Miscellaneous
canSAR (ICR)NTRK2 (select the gene name)
Probes
Litterature
PubMed269 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineNTRK2
EVEXNTRK2
GoPubMedNTRK2
iHOPNTRK2
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Aug 10 18:56:12 CEST 2016

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.